<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02292290</url>
  </required_header>
  <id_info>
    <org_study_id>UOLDR0001N</org_study_id>
    <nct_id>NCT02292290</nct_id>
  </id_info>
  <brief_title>Trial for People With Established Type 2 Diabetes During Ramadan</brief_title>
  <acronym>T4R</acronym>
  <official_title>A Randomised Controlled Trial for People With Established Type 2 Diabetes During Ramadan: Liraglutide vs. a Sulphonylurea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leicester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospitals, Leicester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Leicester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dual therapy with metformin and Liraglutide is more effective at helping people with
      established Type 2 Diabetes Mellitus (T2DM) observing Ramadan achieve a triple composite
      endpoint of weight reduction and/or maintenance and improved HaemaglobinA1c (HbA1c) and no
      severe hypoglycaemic events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants in the control arm will essentially continue with their standard routine care
      and those in the intervention groups will either receive Liraglutide in addition to metformin
      or those on dual therapy will switch from their sulphonylurea/pioglitazone to Liraglutide and
      continue with metformin. Informed consent and baseline data will be collected 4-8 weeks prior
      to the start of Ramadan. This will allow time for a run in period for the titration of
      Liraglutide prior to the fasting period. Ramadan is followed by Eid-al-Fitr a 3-day Islamic
      holiday that marks the end of this holy month. Tradition includes amongst early morning
      prayers/celebration through feasting. Therefore, participants will be invited to attend the
      first follow-up after this event (between weeks 2 - 4) and then at 12 weeks post Ramadan.
      Randomisation will not be revealed until after the baseline data have been collected.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite</measure>
    <time_frame>12 weeks following post Ramadan cinical assessment</time_frame>
    <description>A composite endpoint of a reduction in weight, reduction/maintenance of HbA1c and elimination of severe hypoglycaemic (defined as hospital admission) events post intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c only</measure>
    <time_frame>same as primary, 12 weeks following post Ramadan cinical assessment</time_frame>
    <description>Mean change HbA1c level</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Monotherapy 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>addition of Sulfonylurea or Pioglitazone to Metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dual Therapy 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Swap Liraglutide for sulfonylurea or pioglitazone taken as second line therapy (Metformin) first line)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dual therapy 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Maintain sulfonylurea or pioglitazone as second line therapy (Metformin first line)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Addition of Liraglutide to Metformin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>4 week lead-in 0.6mg Liraglutide OD up to 1.2mg OD after 2 weeks if poor response</description>
    <arm_group_label>Monotherapy</arm_group_label>
    <other_name>Victoza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>4 week lead-in 0.6mg Liraglutide OD up to 1.2mg after two weeks if poor response.</description>
    <arm_group_label>Dual Therapy 1</arm_group_label>
    <other_name>Victoza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfonylurea or Pioglitazone</intervention_name>
    <description>Addition to Metformin</description>
    <arm_group_label>Monotherapy 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maintain dual therapy (Sulf/Pio) as comparator to Liraglutide</intervention_name>
    <description>As per clinical guidelines for prescription</description>
    <arm_group_label>Dual therapy 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Individuals â‰¥ 18 years old with established T2DM on metformin only

          -  or dual therapy of metformin plus a sulphonylurea or pioglitazone

          -  with a HbA1c between 7 - 11 % if on monotherapy and between 6.5 - 12% if on dual
             therapy

        Exclusion Criteria:

          -  Are pregnant or breast feeding

          -  Suffer from terminal illness

          -  Have significant renal or liver impairment

          -  Are unable to provide informed consent

          -  Have severe and enduring mental health problems

          -  Are not primarily responsible for their own care

          -  Are receiving insulin therapy

          -  Type 1 diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melanie J D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Leicester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospitals of Leicester</name>
      <address>
        <city>Leicester</city>
        <state>Leicestershire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2011</study_first_submitted>
  <study_first_submitted_qc>November 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2014</study_first_posted>
  <last_update_submitted>November 14, 2014</last_update_submitted>
  <last_update_submitted_qc>November 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Liraglutide</keyword>
  <keyword>Ramadan</keyword>
  <keyword>fasting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
    <mesh_term>Benzocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

